Copyright
©The Author(s) 2021.
Artif Intell Cancer. Jun 28, 2021; 2(3): 25-41
Published online Jun 28, 2021. doi: 10.35713/aic.v2.i3.25
Published online Jun 28, 2021. doi: 10.35713/aic.v2.i3.25
Vaccine type | Disease | Combination | Phase | NCT ID | |
Tumor cell vaccine | GVAX | Neuroblastoma. Pediatric Solid Tumor | Nivolumab. Ipilimumab | Phase I | NCT04239040 |
Locally Advanced Pancreatic Ductal Adenocarcinoma | Nivolumab CCR2/CCR5 dual antagonist | Phase I; Phase II | NCT03767582 | ||
Metastatic Pancreatic Adenocarcinoma | Epacadostat. Pembrolizumab CRS-207 CY | Phase II | NCT03006302 | ||
Colorectal Cancer | Phase I | NCT01952730 | |||
GVAX Pancreas Vaccine | Pancreatic Cancer | Cyclophosphamide Nivolumab | Phase II | NCT03161379 | |
Pancreatic Cancer | Cyclophosphamide Nivolumab Urelumab | Phase I; Phase II | NCT02451982 | ||
GM-CSF vaccine | Multiple Myeloma | Lenalidomide Prevnar13 | Phase II | NCT03376477 | |
DC Vaccine | AST-VAC2 | NSCLC in the Advanced and Adjuvant Settings | Phase I | NCT03371485 | |
MIDRIXNEO | NSCLC | Antigen-specific DTH. Control DTH | Phase I | NCT04078269 | |
Autologous Dendritic Cell-Adenovirus CCL21 Vaccine | NSCLC Stage IV, IVA, IVB Lung Cancer AJCC v8 | Pembrolizumab | Phase I | NCT03546361 | |
Autologous DCs: MESOVAX | Mesothelioma. Malignant PD-L1 Negative Advanced Cancer Progressive Disease | Pembrolizumab. Interleukin-2 | Phase I | NCT03546426 | |
PEP-DC vaccine | Pancreatic Adenocarcinoma | Phase I | NCT04627246 | ||
ME TARP vaccine | Prostate Cancer | Phase II | NCT02362451 | ||
DC/AML Fusion Vaccine | Acute Myelogenous Leukemia | Decitabine | Phase I | NCT03679650 | |
Acute Myelogenous Leukemia | Phase II | NCT03059485 | |||
mDC3/8-KRAS Vaccine | Pancreatic Ductal Adenocarcinoma | Phase I | NCT03592888 | ||
Autologous DC vaccine: RaC-Ad | Head Neck Tumors, Neuroendocrine Tumors, Soft Tissue Sarcoma Rare Cancer | Interleukin-2 | Phase II | NCT04166006 | |
COREVAX-1 | Stage IV Colorectal Cancer Curative Resection | Interleukin-2 | Phase II | NCT02919644 | |
Autologous DCs + Prevnar 13 | Stage III, IIIA, IIIB, IV, IVA, IVB Hepatocellular Carcinoma AJCC v8, Stage III, IIIA, IIIB, IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Hepatocellular Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma | Radiation: External Beam Radiation Therapy | Early Phase I | NCT03942328 | |
DC Tumor Cell Lysate Vaccine: ATL-DC | Recurrent Glioblastoma | Pembrolizumab poly-ICLC | Phase I | NCT04201873 | |
Dendritic Cell/Tumor Fusion Vaccine | Glioblastoma, Neuroectodermal Tumors | Interleukin-12 Temozolomide | Phase I; Phase II | NCT04388033 | |
DC1 Vaccine+ WOKVAC Vaccine | Female Breast Cancer, Male Breast Cancer, Stage I, II, III Breast Cancer, HER2-positive Breast Cancer | Phase II | NCT03384914 | ||
neoantigen-primed DC vaccine | Gastric Cancer, Hepatocellular Carcinoma, NSCLC, Colon Rectal Cancer | Phase I | NCT04147078 | ||
MG-7-DC vaccine | Later stage of gastric cancer | Sintilimab | Phase I; Phase II | NCT04567069 | |
IKKb matured, RNA-loaded DC vaccine | Melanoma, Uveal Metastatic | Phase II | NCT04335890 | ||
Peptide vaccine | UCPVax: VolATIL | Squamous Cell Carcinoma of the Head and Neck, Anal Canal Cancer, Cervical Cancer | Atezolizumab | Phase II | NCT03946358 |
UCPVax-Glio | Glioblastoma | Phase I; Phase II | NCT04280848 | ||
UCPVax | Metastatic NSCLC | Phase I; Phase II | NCT02818426 | ||
MUC1 | NSCLC | PolyICLC | Phase I; Phase II | NCT01720836 | |
SVN53-67/M57-KLH | Lung Atypical Carcinoid Tumor, Lung Typical Carcinoid Tumor, Metastatic Pancreatic Neuroendocrine Tumor | Incomplete Freund's Adjuvant Octreotide Acetate Sargramostim | Phase I | NCT03879694 | |
NSABP FB-14/AE37 | Triple-negative Breast Cancer | Pembrolizumab | Phase II | NCT04024800 | |
KRAS peptide vaccine | Colorectal Cancer, Pancreatic Cancer | Nivolumab Ipilimumab | Phase I | NCT04117087 | |
da VINc/OTSGC-A24 | Gastric Cancer | Nivolumab Ipilimumab | Phase I | NCT03784040 | |
ARG1-18, 19, 20 | NSCLC, Urothelial Carcinoma, Malignant Melanoma, Ovarian Cancer, Colorectal Cancer, Breast Cancer, Squamous Cell Carcinoma of the Head and Neck, Metastatic Cancer | Phase I | NCT03689192 | ||
Personalized peptide vaccine | Stage IV, IVA, IVB Colorectal Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7 | Imiquimod Pembrolizumab | Phase I | NCT02600949 | |
WT1/NY-ESO-1 | Ovarian Cancer, Fallopian Tube Primary Peritoneal Cancer, Recurrent Ovarian Cancer | Nivolumab | Phase I | NCT02737787 | |
IMU-131/HER-Vaxx | Gastrointestinal Neoplasms, Adenocarcinoma | Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine | Phase I; Phase II | NCT02795988 | |
ESR1 | Breast Cancer | Phase I | NCT04270149 | ||
DNAJB1-PRKACA | Fibrolamellar, Hepatocellular Carcinoma | Nivolumab Ipilimumab | Phase I | NCT04248569 | |
H3.3K27M | Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant | Nivolumab | Phase I; Phase II | NCT02960230 | |
H2NVAC | Ductal Breast Carcinoma In Situ | Granulocyte Macrophage Colony Stimulating Fator | Phase I | NCT04144023 | |
IDH1R132H/AMPLIFY-NEOVAC | Malignant Glioma | Avelumab | Phase I | NCT03893903 | |
DNA Vaccine | pTVG-HP/pTVG-AR | CRPC, Metastatic Cancer | Pembrolizumab rhGM-CSF | Phase II | NCT04090528 |
Mammaglobin-A | Breast Cancer | Phase I | NCT02204098 | ||
pTVG-HP | Prostate Cancer | Nivolumab GM-CSF | Phase II | NCT03600350 | |
pNGVL4a-Sig/E7(detox)/HSP70 | Cervical Cancer, Precancerous Condition, HPV Disease, Human Papilom-virus | Imiquimod | Phase I | NCT00788164 | |
Salmonella oral vaccine | Relapsed Neuroblastoma | Lenalidomide | Early Phase I | NCT04049864 |
- Citation: Wei Q, Fang ZY, Zhang ZM, Zhang TF. Therapeutic tumor vaccines — a rising star to benefit cancer patients. Artif Intell Cancer 2021; 2(3): 25-41
- URL: https://www.wjgnet.com/2644-3228/full/v2/i3/25.htm
- DOI: https://dx.doi.org/10.35713/aic.v2.i3.25